Patents by Inventor Kathryn Packman

Kathryn Packman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for administration
    Patent number: 11738003
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: August 29, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kellie Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • METHOD FOR ADMINISTRATION
    Publication number: 20210069149
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: November 18, 2020
    Publication date: March 11, 2021
    Inventors: Kellie Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • METHOD FOR ADMINISTRATION
    Publication number: 20190328708
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 31, 2019
    Inventors: Kelli Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Combination therapy for proliferative disorders
    Patent number: 9486445
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: November 8, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Brian Higgins, Kenneth Kolinsky, Gwen Nichols, Kathryn Packman, Fei Su
  • COMBINATION THERAPY
    Publication number: 20160256529
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
    Type: Application
    Filed: March 7, 2016
    Publication date: September 8, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Kapil DHINGRA, Brian HIGGINS, Kenneth KOLINSKY, Richard J. LEE, Brian LESTINI, Kathryn PACKMAN, Fei SU
  • Combination therapy for proliferative disorders
    Patent number: 9295669
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: March 29, 2016
    Assignee: Hoffman La-Roche Inc.
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS
    Publication number: 20160051525
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Application
    Filed: July 22, 2015
    Publication date: February 25, 2016
    Inventors: Brian HIGGINS, Kenneth KOLINSKY, Gwen NICHOLS, Kathryn PACKMAN, Fei SU
  • Combination therapy for proliferative disorders
    Patent number: 9216170
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 22, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Brian Higgins, Kenneth Kolinsky, Gwen Nichols, Kathryn Packman, Fei Su
  • METHOD FOR ADMINISTRATION
    Publication number: 20150126575
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Kelli Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Combination therapy
    Patent number: 8709419
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: April 29, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • METHOD FOR ADMINISTRATION
    Publication number: 20130245089
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: February 5, 2013
    Publication date: September 19, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Kelli Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS
    Publication number: 20130245039
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Application
    Filed: February 5, 2013
    Publication date: September 19, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Brian Higgins, Kenneth Kolinsky, Gwen Nichols, Kathryn Packman, Fei Su
  • COMBINATION THERAPY
    Publication number: 20120148533
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
    Type: Application
    Filed: December 7, 2011
    Publication date: June 14, 2012
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • COMBINATION THERAPY
    Publication number: 20120045433
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an topoisomerase inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the topoisomerase inhibitor is irinotecan, or a pharmaceutically acceptable salt thereof, and the disorder is colorectal cancer involving a tumor comprising b-Raf having the V600E mutation.
    Type: Application
    Filed: August 10, 2011
    Publication date: February 23, 2012
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • COMBINATION THERAPY
    Publication number: 20120045434
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.
    Type: Application
    Filed: August 10, 2011
    Publication date: February 23, 2012
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su